Bay Colony Advisory Group Inc d b a Bay Colony Advisors grew its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 9.3% during the 4th quarter, Holdings Channel reports. The firm owned 3,414 shares of the medical research company’s stock after purchasing an additional 290 shares during the quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Amgen were worth $665,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Arlington Partners LLC lifted its holdings in shares of Amgen by 86.7% during the 4th quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock worth $27,000 after acquiring an additional 65 shares during the period. Massey Quick Simon & CO. LLC raised its holdings in Amgen by 710.5% in the fourth quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock valued at $30,000 after buying an additional 135 shares during the period. Contravisory Investment Management Inc. purchased a new position in Amgen in the fourth quarter valued at approximately $50,000. Lavaca Capital LLC purchased a new position in Amgen in the fourth quarter valued at approximately $78,000. Finally, Moody National Bank Trust Division purchased a new position in Amgen in the fourth quarter valued at approximately $81,000. 81.79% of the stock is currently owned by institutional investors.
Several research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $225.00 price target on the stock in a report on Monday, January 14th. BidaskClub lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 29th. Mizuho restated a “buy” rating and issued a $211.00 price target on shares of Amgen in a report on Wednesday. Royal Bank of Canada restated a “neutral” rating on shares of Amgen in a report on Friday, February 1st. Finally, Goldman Sachs Group restated a “buy” rating and issued a $221.00 price target on shares of Amgen in a report on Wednesday, October 31st. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $205.77.
In other news, Director Tyler Jacks sold 20,000 shares of Amgen stock in a transaction that occurred on Thursday, December 6th. The shares were sold at an average price of $195.41, for a total transaction of $3,908,200.00. Following the sale, the director now owns 28,979 shares in the company, valued at $5,662,786.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction that occurred on Thursday, February 7th. The shares were sold at an average price of $190.00, for a total transaction of $380,000.00. Following the sale, the director now owns 14,988 shares in the company, valued at approximately $2,847,720. The disclosure for this sale can be found here. Insiders have sold 23,777 shares of company stock worth $4,648,718 in the last quarter. Insiders own 0.27% of the company’s stock.
AMGN opened at $188.98 on Thursday. The company has a market cap of $119.31 billion, a PE ratio of 13.12, a PEG ratio of 2.06 and a beta of 1.21. Amgen, Inc. has a 52-week low of $163.31 and a 52-week high of $210.19. The company has a debt-to-equity ratio of 2.36, a quick ratio of 2.57 and a current ratio of 2.79.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, January 29th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.26 by $0.16. The company had revenue of $6.23 billion for the quarter, compared to analyst estimates of $5.88 billion. Amgen had a net margin of 35.35% and a return on equity of 66.74%. During the same quarter last year, the firm posted $2.89 earnings per share. Equities research analysts predict that Amgen, Inc. will post 13.93 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be paid a dividend of $1.45 per share. The ex-dividend date is Thursday, February 14th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.07%. This is a positive change from Amgen’s previous quarterly dividend of $1.32. Amgen’s dividend payout ratio (DPR) is currently 36.67%.
ILLEGAL ACTIVITY NOTICE: “Bay Colony Advisory Group Inc d b a Bay Colony Advisors Has $665,000 Holdings in Amgen, Inc. (AMGN)” was originally posted by Macon Daily and is the sole property of of Macon Daily. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://macondaily.com/2019/02/14/bay-colony-advisory-group-inc-d-b-a-bay-colony-advisors-has-665000-holdings-in-amgen-inc-amgn.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Further Reading: Quiet Period Expirations Explained
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.